Tamoxifen as first-line treatment in a premenarchal girl with juvenile breast hypertrophy

Korcan Demir; Tolga Unuvar; Sanem Eren; Ayhan Abaci; Ece Bober

doi:10.1016/j.jpag.2009.11.003

Tamoxifen as first-line treatment in a premenarchal girl with juvenile breast hypertrophy

J Pediatr Adolesc Gynecol. 2010 Oct;23(5):e133-6. doi: 10.1016/j.jpag.2009.11.003.

Authors

Korcan Demir¹, Tolga Unuvar, Sanem Eren, Ayhan Abaci, Ece Bober

Affiliation

¹ Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.

PMID: 20813327
DOI: 10.1016/j.jpag.2009.11.003

Abstract

Background: Juvenile breast hypertrophy is uncommon and is characterized by excessive breast enlargement in the peripubertal period. The clinical entity is thought to result from increased sensitivity of mammary tissue to normal levels of circulating hormones.

Case: Here, we report a female patient, aged 12 years and 6 months, suffering from juvenile breast hypertrophy, who presented at the third month of symptoms and benefited from tamoxifen treatment.

Comments: In experienced clinics, use of tamoxifen in the treatment of juvenile breast hypertrophy during the brisk growth period may become a medical alternative to reconstructive surgery.

Publication types

Case Reports

MeSH terms

Breast / abnormalities
Breast / pathology*
Child
Female
Humans
Hypertrophy / drug therapy
Selective Estrogen Receptor Modulators / therapeutic use*
Tamoxifen / therapeutic use*

Substances

Selective Estrogen Receptor Modulators
Tamoxifen

Supplementary concepts

Gigantomastia